These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29474655)

  • 1. Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activity.
    Bodewes ILA; Al-Ali S; van Helden-Meeuwsen CG; Maria NI; Tarn J; Lendrem DW; Schreurs MWJ; Steenwijk EC; van Daele PLA; Both T; Bowman SJ; Griffiths B; Ng WF; ; Versnel MA
    Rheumatology (Oxford); 2018 May; 57(5):921-930. PubMed ID: 29474655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
    Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
    Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome.
    Maria NI; Brkic Z; Waris M; van Helden-Meeuwsen CG; Heezen K; van de Merwe JP; van Daele PL; Dalm VA; Drexhage HA; Versnel MA
    Ann Rheum Dis; 2014 Jun; 73(6):1052-9. PubMed ID: 23831963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of cigarette smoking with disease phenotype and type I interferon expression in primary Sjögren's syndrome.
    Olsson P; Bodewes ILA; Nilsson AM; Turesson C; Jacobsson LTH; Theander E; Versnel MA; Mandl T
    Rheumatol Int; 2019 Sep; 39(9):1575-1584. PubMed ID: 31139950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
    Seror R; Theander E; Brun JG; Ramos-Casals M; Valim V; Dörner T; Bootsma H; Tzioufas A; Solans-Laqué R; Mandl T; Gottenberg JE; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Valesini G; Bartoloni E; Saraux A; Tomsic M; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Vitali C; Mariette X; Bowman SJ;
    Ann Rheum Dis; 2015 May; 74(5):859-66. PubMed ID: 24442883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
    Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
    Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
    Seror R; Theander E; Bootsma H; Bowman SJ; Tzioufas A; Gottenberg JE; Ramos-Casals M; Dörner T; Ravaud P; Mariette X; Vitali C
    J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein and DNA methylation-based scores as surrogate markers for interferon system activation in patients with primary Sjögren's syndrome.
    Björk A; Richardsdotter Andersson E; Imgenberg-Kreuz J; Thorlacius GE; Mofors J; Syvänen AC; Kvarnström M; Nordmark G; Wahren-Herlenius M
    RMD Open; 2020 Jan; 6(1):. PubMed ID: 31958277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
    Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
    Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
    Seror R; Gottenberg JE; Devauchelle-Pensec V; Dubost JJ; Le Guern V; Hayem G; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Morel J; Pedriger A; Puechal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Zarnitsky C; Labetoulle M; Ravaud P; Mariette X
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of systemic activity of pediatric primary Sjögren's syndrome by EULAR Sjögren's syndrome disease activity index (ESSDAI).
    Kobayashi I; Okura Y; Ueki M; Tozawa Y; Takezaki S; Yamada M; Ariga T
    Mod Rheumatol; 2019 Jan; 29(1):130-133. PubMed ID: 29529894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity.
    Mandl T; Marsal J; Olsson P; Ohlsson B; Andréasson K
    Arthritis Res Ther; 2017 Oct; 19(1):237. PubMed ID: 29065905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.
    Seror R; Ravaud P; Bowman SJ; Baron G; Tzioufas A; Theander E; Gottenberg JE; Bootsma H; Mariette X; Vitali C;
    Ann Rheum Dis; 2010 Jun; 69(6):1103-9. PubMed ID: 19561361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated unphosphorylated STAT1 and IRF9 in T and B cells of primary sjögren's syndrome: Novel biomarkers for disease activity and subsets.
    Ritter J; Szelinski F; Aue A; Stefanski AL; Rincon-Arevalo H; Chen Y; Nitschke E; Dang VD; Wiedemann A; Schrezenmeier E; Lino AC; Dörner T
    J Autoimmun; 2024 Jul; 147():103243. PubMed ID: 38788537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren's syndrome.
    Maria NI; Steenwijk EC; IJpma AS; van Helden-Meeuwsen CG; Vogelsang P; Beumer W; Brkic Z; van Daele PL; van Hagen PM; van der Spek PJ; Drexhage HA; Versnel MA
    Ann Rheum Dis; 2017 Apr; 76(4):721-730. PubMed ID: 27672125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies.
    Acar-Denizli N; Horváth IF; Mandl T; Priori R; Vissink A; Hernandez-Molina G; Armagan B; Praprotnik S; Sebastian A; Bartoloni E; Rischmueller M; Pasoto SG; Nordmark G; Nakamura H; Fernandes Moça Trevisani V; Retamozo S; Carsons SE; Maure-Noia B; Sánchez-Berná I; López-Dupla M; Fonseca-Aizpuru E; Melchor Díaz S; Vázquez M; Díaz Cuiza PE; de Miguel Campo B; Ng WF; Rasmussen A; Dong X; Li X; Baldini C; Seror R; Gottenberg JE; Kruize AA; Sandhya P; Gandolfo S; Kwok SK; Kvarnstrom M; Solans R; Sene D; Suzuki Y; Isenberg DA; Valim V; Hofauer B; Giacomelli R; Devauchelle-Pensec V; Atzeni F; Gheita TA; Morel J; Izzo R; Kalyoncu U; Szántó A; Olsson P; Bootsma H; Ramos-Casals M; Kostov B; Brito-Zerón P;
    Clin Exp Rheumatol; 2020; 38 Suppl 126(4):85-94. PubMed ID: 33095152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome.
    de Wolff L; Arends S; Pontarini E; Bombardieri M; Bowman SJ; Bootsma H
    Clin Exp Rheumatol; 2021; 39 Suppl 133(6):100-106. PubMed ID: 34796851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies.
    Seror R; Meiners P; Baron G; Bootsma H; Bowman SJ; Vitali C; Gottenberg JE; Theander E; Tzioufas A; De Vita S; Ramos-Casals M; Dörner T; Quartuccio L; Ravaud P; Mariette X;
    Ann Rheum Dis; 2016 Nov; 75(11):1945-1950. PubMed ID: 27150113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.